Vertex Pharmaceutica
VRTX
Delayed Nasdaq - 01/18 10:00:00 pm
157.19USD
+0.13%
Income Statement Evolution
Annual Income Statement Data
Actuals in M $ Estimates in M $
Fiscal Period December 20162017
Sales1 7012 334
EBITDA350564
Operating profit (EBIT)288538
Pre-Tax Profit (EBT)--
Net income-112294
EPS ( $ )-0,461,00
Dividend per Share ( $ )--
Yield--
Announcement Date01/25/2017
09:01pm
-
Finances - Leverage
Actuals in M $ Estimates in M $
Fiscal Period December 20162017
Debt--
Finance893933
Operating income (EBITDA)350564
Leverage
(Debt/EBITDA)
--
Capital Expenditure70,865,8
Book Value Per Share (BVPS)4,66 $7,00 $
Cash Flow per Share0,96 $2,02 $
Announcement Date01/25/2017
09:01pm
-
Balance Sheet Analysis
Financial Ratios
Size 2017e 2018e
Capitalization 39 703 M$ -
Entreprise Value (EV) 38 770 M$ 38 096 M$
Valuation 2017e 2018e
P/E ratio (Price / EPS) 157x 84,9x
Capitalization / Revenue 17,0x 14,5x
EV / Revenue 16,6x 13,9x
EV / EBITDA 68,8x 44,8x
Yield (DPS / Price) - -
Price to book (Price / BVPS) 22,4x 17,7x
Profitability 2017e 2018e
Operating Margin (EBIT / Sales) 23,0% 29,4%
operating Leverage (Delta EBIT / Delta Sales) 2,32x 2,88x
Net Margin (Net Profit / Revenue) 12,6% 16,7%
ROA (Net Profit / Asset) 12,9% 25,9%
ROE (Net Profit / Equities) 29,8% 47,1%
Rate of Dividend - -
Balance Sheet Analysis 2017e 2018e
CAPEX / CA   2,82% 2,56%
Cash Flow / Sales 21,8% 32,8%
Capital Intensity (Assets / Sales) 0,98x 0,64x
Financial Leverage (Net Debt / EBITDA) -1,66x -1,89x
Price Earning Ratio
BNA & Dividende